SODIUM ACETATE Drug Patent Profile

Which patents cover Sodium Acetate, and when can generic versions of Sodium Acetate launch?

Sodium Acetate is a drug marketed by Amneal, Extrovis, Fresenius Kabi Usa, Hikma, Hospira, Milla Pharms, and Somerset Theraps Llc. and is included in seven NDAs.

The generic ingredient in SODIUM ACETATE is sodium acetate. Six suppliers are listed for this compound. Additional details are available on the sodium acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sodium Acetate

A generic version of SODIUM ACETATE was approved as sodium acetate by HOSPIRA on May 4^th, 1983.

Summary for SODIUM ACETATE

US Patents:	0
Applicants:	7
NDAs:	7

US Patents and Regulatory Information for SODIUM ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	SODIUM ACETATE	sodium acetate	SOLUTION;INTRAVENOUS	218469-003	Mar 2, 2026	AP	RX	No	No
Somerset Theraps Llc	SODIUM ACETATE	sodium acetate	SOLUTION;INTRAVENOUS	219826-002	Sep 18, 2025	AP	RX	No	No
Hikma	SODIUM ACETATE	sodium acetate	SOLUTION;INTRAVENOUS	216920-001	Mar 15, 2024	AP	RX	No	No
Extrovis	SODIUM ACETATE	sodium acetate	SOLUTION;INTRAVENOUS	220274-001	Apr 17, 2026	AP	RX	No	No
Hospira	SODIUM ACETATE	sodium acetate	SOLUTION;INTRAVENOUS	018893-003	Sep 2, 2014	AP	RX	Yes	Yes
Hikma	SODIUM ACETATE	sodium acetate	SOLUTION;INTRAVENOUS	216920-002	Mar 15, 2024	AP	RX	No	No

Last updated: July 27, 2026

Sodium Acetate Investment Scenario and Fundamentals Analysis (2026): Patent, Exclusivity, FDA Status, and Commercial Risk

Sodium acetate is a widely used excipient/active ingredient in pharmaceuticals and critical care fluids, with commercial reality driven by bulk commodity supply, grade specifications, and formulation inclusion rather than proprietary blockbuster IP. Investment case strength is therefore tied to (1) regulatory status by product and route, (2) supply-chain reliability and manufacturing barriers for specific grades (USP/NF, injectable), and (3) whether any sodium acetate products in a portfolio are protected by narrow formulation, method, or use patents and associated FDA exclusivities. Patent-led value creation is typically limited; risk-adjusted returns depend on sourcing leverage, cost curve positioning, and contracting dynamics with hospitals and distributors.

---

Is sodium acetate patent protected, and what patents cover sodium acetate products?

Are sodium acetate patents meaningful for investors

For sodium acetate, the core molecule is generally not a proprietary invention. Value capture usually shifts to:

• Specific injectable presentations (concentration, container closure system).
• Manufacturing controls (purity profiles, endotoxin/sterility, ion balance).
• Specific therapeutic uses (if claimed) that tie to an FDA-approved drug product rather than to the salt itself.
• Combination products (sodium acetate paired with other actives) and specific infusion protocols.

Where patent protection typically exists

Patent estates for sodium acetate-related products usually fall into these buckets:

• Manufacturing methods for high-purity sodium acetate suitable for injection.
• Sterile filtration/aseptic processing controls that tie to validated impurity limits.
• Formulation/process patents for buffered infusion solutions or alkalinization regimens.
• Container/packaging compatibility (less common for commodity salts, more common for finished sterile solutions).

How to evaluate sodium acetate patent estates

For an investment diligence checklist, focus on whether the relevant IP is:

• Listed in the FDA Orange Book for an approved sodium acetate drug product (not just excipient monographs).
• Directed at a specific strength and dosage form (injectable, oral solution, etc.).
• Tied to a specific route of administration and label dosing regimen.

If sodium acetate is used only as an excipient in other branded drugs, the excipient itself rarely has investable exclusivity. The investability concentrates in finished dosage forms that compete directly in procurement.

---

When does sodium acetate lose exclusivity, and how long is exclusivity for sodium acetate products?

Exclusivity usually comes from the finished drug product

Sodium acetate does not have a “single exclusivity date” in the way a branded new chemical entity does. Exclusivity is product-specific:

• If the product is an NDA/ANDA with Orange Book exclusivity, it follows NDA regulatory timelines.
• If marketed as a compendial excipient or bulk ingredient, exclusivity is effectively absent.

Typical exclusivity pathways to check

For any investor targeting a sodium acetate finished product:

• New Drug Application (NDA) exclusivity (5-year NCE, 3-year new clinical investigations, 7-year orphan).
• Patent exclusivity under the Orange Book listing.
• Section 505(b)(2) exclusivity where sodium acetate is part of a formulation and the applicant relies on prior studies for the underlying product.

Featured snippet answer

There is no universal sodium acetate exclusivity. The only enforceable timelines are those tied to a specific FDA-approved sodium acetate drug product and its listed patents/exclusivities in the Orange Book.

---

What is the Orange Book status of sodium acetate?

Orange Book is the gating item for patent-backed investment

A credible, patent-led investment thesis requires:

• Sodium acetate drug product entries in FDA’s Orange Book.
• Active listings for patents (composition, formulation, method of use, manufacturing).
• Current status: “expired,” “expires on,” “patent active,” and whether exclusivity protects marketing.

How to interpret an Orange Book footprint

• No Orange Book listing for the sodium acetate product: investable value is likely supply and execution, not IP.
• Multiple Orange Book patents: evaluate whether they are composition/formulation/manufacturing or merely process controls that generic entrants can avoid.
• Short remaining patent life: plan on volume erosion and margin compression tied to generic entry.

---

Which companies supply sodium acetate, and how does competition impact pricing?

Competitive landscape drivers

Sodium acetate pricing and margin stability track:

• Bulk commodity inputs (acetic acid feedstocks) and regional capacity.
• Specialty grade demand for injection and controlled impurity specifications.
• Distributor contracting models and hospital formulary adoption.

What matters more than brand

For sodium acetate, procurement and competition usually center on:

• Ability to pass injectable-grade qualification and batch release testing.
• Lead times and fill-finish capacity for sterile/aseptic product lines.
• Documentation packages (CoA, impurity profiles, endotoxin/sterility validation).

Investment implication

The main market risk is not patent cliffs. It is:

• Capacity additions that force price normalization.
• Quality recalls or regulatory actions that redirect supply away from a manufacturer.
• Customer concentration in health systems, group purchasing organizations (GPOs), and distributors.

---

What formulations are protected by patents for sodium acetate (injectable vs oral vs buffered solutions)?

Injectable formulations

Where patent protection is most likely is in injectable finished products, where investors should check:

• Sterile, pyrogen-controlled manufacturing and release methods.
• Specific strengths and buffers used for alkalinization or infusion protocols.
• Stability data tied to shelf life under specific storage conditions.

Combination and buffered solutions

If sodium acetate appears in:

• Buffered IV fluids,
• Acid-base management infusion regimens,
• Renal or perioperative alkalinization protocols, then the investable IP may attach to the finished product formulation rather than to sodium acetate alone.

Investor diligence

Map patents to:

• Dosage form (solution vs injection),
• container (glass vs plastic),
• concentration (mEq/mL or % w/v),
• stability and storage (USP conditions),
• method of manufacture (sterile filtration, aseptic fill, cleaning validation).

---

What method-of-use patents exist for sodium acetate, and do they create enforceable barriers?

Method-of-use barriers are usually narrow

If a method-of-use patent exists, enforceability typically depends on:

• Whether the patent is listed and tied to the FDA label indication.
• Whether clinical practice triggers infringement (direct or induced).
• Whether competitors can design around by using different dosing regimens or alternative alkalinization agents.

Practical investor conclusion

Method-of-use protection for a commodity salt is usually hard to defend unless:

• It is strongly label-tied and uniquely claimed,
• There is active enforcement with a clear litigation record.

---

What patent litigation affects sodium acetate, and which settlements signal entry risk?

Litigation tends to be product-specific

For sodium acetate, litigation risk emerges when:

• A sodium acetate finished drug product is listed in the Orange Book.
• A generic or 505(b)(2) applicant files an ANDA/505(b)(2) with a Paragraph IV challenge.

What settlements would imply

• Early settlement before first generic approval: indicates real patent strength or commercial need to delay entry.
• Settlement with delayed launch: indicates likely enforceability or sufficient commercial value to buy off risk.
• No meaningful settlement record: suggests limited enforceable IP and reliance on supply capability.

---

How does sodium acetate compare with alternatives for alkalinization and buffered infusion?

Direct competition is substitution-driven

In clinical use (notably acid-base management and buffered IV infusions), sodium acetate often competes against:

• Sodium bicarbonate,
• Sodium lactate,
• Carbocisteine/other acid-base strategies depending on indication,
• Other alkalinizing salts or buffered solutions.

How substitution changes investment economics

• If alternatives are clinically interchangeable, pricing compresses quickly once multiple suppliers exist.
• If a specific product provides distinct stability, compatibility, or administration advantages, it can sustain pricing longer even without patents.

---

What generic entry risks exist for sodium acetate products?

Primary risk is product-level genericization

If the product is an injectable sodium acetate solution with Orange Book patents:

• Generic entry risk is tied to patent expiration and exclusivity windows.
• Paragraph IV challenges can accelerate generic launch if patents are weak.

Secondary risk is supply switching

Even absent legal barriers, purchasers can switch to:

• Alternate grades,
• Alternate packaging,
• Alternate suppliers meeting qualification.

So investment should treat generic risk as both legal and operational.

---

How strong is the patent estate for sodium acetate, and what is typical enforceability?

Usual pattern

For salts and widely used excipients:

• Many patents, if any, focus on incremental manufacturing or formulation details.
• Broad composition claims are less common and harder to defend.
• Enforcement tends to be narrow and fact-dependent.

Investor scoring model

Use a binary framework when data is available in the Orange Book and litigation dockets:

• Score 1: Orange Book listed patents with multiple years remaining.
• Score 2: Patent claims appear formulation/manufacturing that are hard to design around.
• Score 3: There is active litigation history with sustained injunction outcomes.
• Score 0: No Orange Book listings for sodium acetate product entries.

This matters because the capital markets typically require durable exclusion to underwrite sustained margins.

---

FDA regulatory status for sodium acetate: what approvals matter for investment?

Assess approval type

Investable sodium acetate exposure comes through finished dosage forms with:

• NDA/ANDA approval,
• 505(b)(2) approvals,
• Current labeling and manufacturing site status.

If the exposure is commodity sodium acetate:

• The regulatory story is more about quality system compliance and grade specifications than about NDA exclusivity.

Key regulatory diligence points

• Current Good Manufacturing Practice (cGMP) compliance history.
• Batch release and impurity control.
• Sterility assurance level and endotoxin testing for injectables.
• Label manufacturing changes and any FDA Form 483 observations.

---

Revenue exposure: where sodium acetate demand is concentrated and how it moves

Demand drivers

Demand is tied to:

• Hospital utilization of alkalinization and buffered infusion regimens.
• Surgical and critical care patient loads.
• Availability constraints during supply disruptions.

Margin drivers

Margins depend on:

• Ability to source feedstock at low cost,
• Yield and conversion efficiency,
• Sterile fill-finish capacity utilization (for injectables),
• Contract pricing cycles with distributors and health systems.

Key commercial risk

Sodium acetate is exposed to:

• Price normalization from new supply,
• Quality incidents that cause customer qualification delays,
• Inventory cycles that swing working capital.

---

Geographic coverage: where sodium acetate supply and regulation drive business value

Investment-relevant geographies

• US: governed by FDA approval status and cGMP enforcement for finished dosage forms.
• EU/UK: regulated by EMA and national competent authorities for product dossiers; excipient monographs still drive specification.
• Emerging markets: procurement and supply assurance can outweigh IP.

Global strategy

If investing in manufacturing:

• Localization and regulatory approval for specific sites can create barriers.
• If investing in distribution:
• Regulatory qualification and reliability matter more than patent duration.

---

Key takeaways for an investment scenario

• Sodium acetate is typically not a patent-led opportunity at the molecule level; the investable unit is the specific FDA-approved sodium acetate finished product (injectable/oral/solution) with Orange Book listed patents and enforceable exclusivities.
• Exclusivity and expiration timelines are product-specific and depend on Orange Book patent listings and exclusivity designations.
• Competitive risk is primarily supply-chain and procurement-driven, with genericization and substitution accelerating margin compression once multiple qualified suppliers exist.
• The most actionable diligence work is mapping (1) Orange Book status, (2) remaining patent life by strength and dosage form, and (3) any Paragraph IV or settlement history for sodium acetate product entries.
• Returns hinge on manufacturing reliability, batch quality performance, and contracting leverage more than on broad IP exclusivity.

---

FAQs

1) Does sodium acetate have NCE or 5-year exclusivity like branded drugs?

Not as a general rule. Exclusivity depends on a specific FDA-approved sodium acetate finished product and its regulatory approval history.

2) Can generic manufacturers enter sodium acetate injectables before patent expiry?

Only if Orange Book patents do not block the specific generic product claim set, or if patents are invalid/unenforceable via litigation or settlement outcomes.

3) What evidence most strongly predicts margin pressure in sodium acetate?

New qualified supply entering the same strength/dosage form, coupled with distributor and hospital contract rebasing after competitive tender cycles.

4) Are manufacturing method patents enough to stop competitors for sodium acetate?

They can slow design-around if claims are specific and hard to avoid, but they are often narrow and operationally avoidable.

5) Is investment more attractive in sodium acetate excipient supply or finished injectable products?

Finished injectable products can carry more regulatory and qualification barriers, but investment value still depends on whether Orange Book-listed patents/exclusivities exist and have remaining life.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book). https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. FDA. Patent and Exclusivity for Drugs. https://www.fda.gov/drugs/patent-and-exclusivity-information-sources-drugs